BCI-215 is primarily investigated for its potential therapeutic applications in cancer treatment. It functions as a targeted inhibitor, specifically designed to disrupt certain cellular pathways that are crucial for cancer cell survival and proliferation. By inhibiting these pathways, BCI-215 aims to induce apoptosis (programmed cell death) in cancer cells while sparing healthy tissues, thereby reducing the side effects commonly associated with traditional chemotherapy. Research is ongoing to evaluate its efficacy in various cancer types, particularly those that are resistant to conventional treatments. Additionally, its mechanism of action is being studied to understand its potential in combination therapies, where it could enhance the effectiveness of other anticancer drugs.